1. Introduction {#s0005}
===============

The genus *Hibiscus* contains about 275 species of flowering plants in the tropics and sub-tropics. Its vitamin C rich flowers are edible with distinct tangy flavor that can be dried, candied, baked as cakes and blended into tea. The calyces are generally decocted and consumed as cold or hot beverage ([@b0115]). Cancer, considered as a major health problem worldwide which is responsible for approximately 7.6 million deaths (13% of all deaths) per annum. In spite of the advancement in the area of cancer probe there is still an urgency to find new anti-cancer agents. Taking into account of the progressing requirement for the potent anticancer agents, and relationship of nutritional therapy with diminished cancer risk, eatable plants are progressively considered as good source of anticancer agents ([@b0090]). Several *Hibiscus* species such as *H. syriacus* reported to possess excellent cytotoxic effect on lung, breast and liver cancer cells ([@b0055], [@b0085]), and its phytoconstituent betulin-3-caffeate (triterpene) showed strong cytotoxic potential against human lung cancer cells, A549 (IC~50~, 4.3 μM) ([@b0120]); *H. sabdariffa* L., exhibited excellent cytotoxic property against human gastric carcinoma cells ([@b0090]) and its constituent delphinidin 3-sambubioside (anthocyanin) induced apoptosis in human leukemia cells ([@b0065]). *H. deflersii* was found to possess antidiarrhetic and antiphologistic activities while the leaves were very effective in heart disorders and diabetes ([@b0080]). *H. micranthus* widely available in southern and western province of Saudi Arabia ([@b0075]) reported to contain stronger anti-fungal, antiviral and anti-tumor activity ([@b0110]) as well as antibacterial and wound healing properties ([@b0040]).

The HPTLC (High Performance Thin Layer Chromatography) has been widely employed these days in the quality control of herbs and its formulations due to its small mobile phase requirement and multi sample analysis which reduces the cost and time of study. It provides a complete profile of a plant extract by using different wavelengths of light that is typically observed with more specific types of analyses. It is more precise and calibrated, and has several advantages over other analytical technique like HPLC (high performance liquid chromatography) in quantification of different markers (both UV active or inactive). The broad dimensions of stationary phases has increased the utilization of HPTLC for a wide range of samples ([@b0130], [@b0035], [@b0030], [@b0025], [@b0020], [@b0125], [@b0005], [@b0015]).

The excellent pharmacological properties shown by *Hibiscus* species motivated the authors to explore the anticancer property of *H. calyphyllus, H. deflersii* and *H. micranthus* grown in Saudi Arabia, including concurrent analysis of cytotoxic biomarkers ursolic acid (A), β-sitosterol (B) and lupeol (C) ([Fig. 1](#f0005){ref-type="fig"}) by validated HPTLC method.Fig. 1Anticancer biomarkers of plant origin.

2. Experimental {#s0010}
===============

2.1. Apparatus and reagents {#s0015}
---------------------------

The three anticancer biomarkers, ursolic acid, β-sitosterol and lupeol were procured from Sigma Aldrich (USA). The solvents used (petroleum ether, ethyl acetate, toluene, chloroform, ethyl acetate, methanol and n-butanol; AR grade) were purchased from BDH (UK). The HPTLC plates (glass-backed silica gel 60F~254~) were purchased from Merck (Germany). The application of biomarkers and extracts (band wise) to the plate was carried out by Automatic TLC Sampler-4 (CAMAG, Switzerland) while the development took place in automatic development chamber (ADC2, Switzerland). The developed plate was derivatized with *p*-anisaldehyde reagent \[the reagent was prepared according to the [@b0140] by using anisaldehyde, glacial acetic acid, methanol and concentrated sulphuric acid. Initially anisaldehyde (0.5 mL) was mixed with glacial acetic acid (10 mL) followed by addition of methanol (85 mL) and then sulphuric acid (5 mL)\]. The scanning and documentation of developed HPTLC plate was carried out by CATS 4 (CAMAG, Switzerland) and TLC Reprostar 3 (CAMAG, Switzerland), respectively.

2.2. Plant material {#s0020}
-------------------

Aerial parts of *H. calyphyllus* Cav. (Voucher No. HA-234)*, H. deflersii* Schweinf. ex Cufod. (Voucher No. HA-567) and *H. micranthus* L. (Voucher No. HA-16240) were collected from As-Sahla mountain of Asir region (Kingdom of Saudi Arabia), authenticated and the specimen were deposited in the herbarium of Pharmacognosy Department, Pharmacy College (King Saud University, Riyadh). The aerial parts of all samples were washed thoroughly, chopped into small pieces and spread uniformly on aluminum trays. Further the samples were shade dried, coarsely powdered and stocked in sealed container for other use.

2.3. Extraction of plant material {#s0025}
---------------------------------

The extraction of powder (400 g) of all three *Hibiscus* species was carried out in 95% ethanol according to the [@b0130]. The obtained extracts were fractionated using various solvents (petroleum ether, toluene, chloroform, ethyl acetate, and n-butanol), yield was calculated and stored at 4 °C in refrigerator as *H. calyphyllus* \[HcP (petroleum ether fraction, 2.25 g), HcT (toluene fraction, 2.21 g), HcC (chloroform fraction, 3.32 g), HcE (ethyl acetate fraction, 2.3 g) and HcB (n-butanol fraction, 2.01 g)\]; *H. deflersii* \[HdP (petroleum ether fraction, 1.19 g), HdT (toluene fraction, 2.10 g), HdC (chloroform fraction, 2.46 g), HdE (ethyl acetate fraction, 2.37 g) and HdB (n-butanol fraction, 1.98 g)\] and *H. micranthus* \[HmP (petroleum ether fraction, 1.96 g), HmT (toluene fraction, 2.36 g), HmC (chloroform fraction, 2.55 g), HmE (ethyl acetate fraction, 2.86 g) and HmB (n-butanol fraction, 2.01 g)\] until the time of use.

2.4. Anticancer activity of different fractions of all *Hibiscus* species {#s0030}
-------------------------------------------------------------------------

A human liver cancer cell line (HepG2) and breast cancer cell line (MCF-7) were grown and preserved in culture media DMEM-Glutmax, supplemented with 10% bovine calf serum and 1x penicillin--streptomycin (all from Invitrogen, USA) at 37 °C with 5% CO~2~ supply. The cells were seeded (0.5x10^5^ cells/well in triplicate) in a 96-well flat-bottom plate (Becton-Dickinson Labware) a day before treatment and grown. The preparation of stock solution (1.0 mg/mL) of all the compounds were accomplished in DMSO (Sigma) and additional working dilutions were prepared in culture media. Cells were treated with three different doses of HcP, HcT, HcE, HcC, HcB, HdP, HdT, HdE, HdC, HdB, HmP, HmT, HmE, HmC and HmB (300, 150 and 75 mg/mL; in triplicate) including vinblastin (standard) and an untreated control, and further incubated for 48 h. The TACS MTT Cell Proliferation and Viability Assay Kit (TACS) were used to perform the Cell proliferation and viability test as per the instructions of manufacturer. The cancer cell lines survival curve was obtained by plotting the relationship between surviving fraction and extract concentration. The estimation of response parameter IC~50~ value (the concentration required for 50% inhibition of cell viability) was carried out by using the best fit regression curve method in Excel.

2.5. Concurrent analysis of biomarkers ursolic acid, β-sitosterol and lupeol in different *Hibiscus species* by High Performance Thin Layer Chromatography (HPTLC) {#s0035}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 2.5.1. HPTLC instrumentation and conditions {#s0040}

The HPTLC analyses of ursolic acid, β-sitosterol and lupeol in sample (15 fractions) were accomplished on normal phase (NP) HPTLC plates (20 × 10 cm). All the markers as well as the extract were applied on HPTLC plate at a rate of 160 nL/s using microlitre syringe fitted with the automatic TLC Sampler-4. The plate development took place in a pre-saturated twin-trough glass chamber (20 × 10 cm) under the chamber saturation condition (at 25 ± 2 °C and 60 ± 5% humidity). Further, the plates were dried and derivatized with p-anisaldehyde reagent to furnish compact spots of the biomarkers and the phytoconstituents available in the different fractions. The plates were then analyzed quantitatively at λ = 575 nm (wavelength) in absorbance mode.

### 2.5.2. Preparation of stock solutions (standards) {#s0045}

A stock solution (1 mg/mL) of standard (ursolic acid, β-sitosterol and lupeol) was prepared in chloroform followed by further dilution to make seven different concentrations (10--120 μg/mL). 10 μL of each concentration of ursolic acid, β-sitosterol and lupeol were applied on the HPTLC plate to provide a linearity range of 100--1200 ng/band.

### 2.5.3. Method validation {#s0050}

The validation of the HPTLC method was carried out as per the ICH guideline ([@b0070]) for LOD (limit of detection), LOQ (limit of quantification), linearity range, precision, recovery as accuracy and robustness determination.

2.6. Statistical analysis {#s0055}
-------------------------

The one-way analysis of variance (ANOVA) and Dunnet's test was used in statistical analysis to estimate the total variation in a set of data. The obtained results were denoted as mean ± SD where, P \< 0.05 was considered as significant.

3. Results and discussion {#s0060}
=========================

3.1. Anticancer activity of different fractions of all *Hibiscus* species {#s0065}
-------------------------------------------------------------------------

The different fractions of *H. calyphyllus* (HcP, HcT, HcE, HcC, HcB), *H. deflersii* (HdP, HdT, HdE, HdC, HdB) and *H. micranthus* (HmP, HmT, HmE, HmC, HmB) were evaluated for their *in vitro* anticancer activities against HepG2 and MCF-7 cells showed marked toxicity ([Table 1](#t0005){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Various fractions of *Hibiscus* species exhibited strong anticancer property against HepG2 \[(IC~50~): HdP(14.4) \> HcP(14.5) \> HdC(14.8) \> HcC(24.4) \> HcE(26) \> HmE(27.4) \> HmC(27.6)\] as well as MCF-7 cells \[(IC~50~): HdP(11.1) \> HmC(24.1) \> HcP(25.1) \> HdE(27.8) \> HdC(30.6)\]. This result indicated that the petroleum ether fraction of *H. deflersii* (HdP; IC~50~: 14.4 and 11.1 μg/mL) possessed the strong anticancer property against both cells in comparison to the standard vinblastin (IC~50~: 3.48 and 5.44 μg/mL). This was supported by the results of HPTLC analysis in which the maximum presence of cytotoxic biomarkers ursolic acid, β-sitosterol and lupeol was found in HdP fraction.Table 1The estimated IC~50~ (μg/mL) values of different fractions of *H. calyphyllus*, *H. deflersii*, and *H. micranthus.*IC~50~ (μg/mL) values of different fractions of *H. calyphyllus*IC~50~ (μg/mL) values of differentfractions of *H. deflersii*IC~50~ (μg/mL) values of different fractions of *H. micranthus*FractionsIC~50~ (µg/mL) ± SD (HepG2 cells)IC~50~ (µg/mL) ± SD (MCF-7 cells)FractionsIC~50~ (µg/mL) ± SD (HepG2 cells)IC~50~ (µg/mL) ± SD (MCF-7 cells)FractionsIC~50~ (µg/mL) ± SD (HepG2 cells)IC~50~ (µg/mL) ± SD (MCF-7 cells)HcT96.9 ± 1.3224 ± 5.8HdT54.1 ± 2.558 ± 3.4HmT117 ± 8.2216 ± 8.6HcP14.5 ± 0.825.1 ± 1.1HdP14.4 ± 0.811.1 ± 0.5HmP118 ± 4.5104 ± 5.2HcC24.4 ± 1.294.6 ± 1.4HdC14.8 ± 0.630.6 ± 0.8HmC27.6 ± 1.224.1 ± 0.6HcE26 ± 1.8118 ± 4.6HdE103 ± 9.227.8 ± 1.1HmE27.4 ± 1.854.1 ± 3.8HcB98.8 ± 3.6520 ± 3.0HdB54.8 ± 0.9265 ± 5.9HmB118 ± 4.5411 ± 12.3Vinblastin (Stand.)3.48 ± 0.225.44 ± 0.57Vinblastin (Stand.)3.48 ± 0.225.44 ± 0.57Vinblastin (Stand.)3.48 ± 0.225.44 ± 0.57Fig. 2Cytotoxic activity of different fractions of *H. calyphyllus*, *H. deflersii* and *H. micranthus* against Hep-G2 cell line at different concentrations (3.9--125 µg/mL). (A) The% viability of HepG2 cell treated with *H. calyphyllus* fractions. (B) The% viability of HepG2 cell treated with *H. deflersii* fractions. (C) The% viability of HepG2 cell treated with *H. micranthus* fractions.Fig. 3Cytotoxic activity of different fractions of *H. calyphyllus*, *H. deflersii* and *H. micranthus* against MCF-7 cell line at different concentrations (3.9--125 µg/mL). (A) The% viability of MCF-7 cell treated with *H. calyphyllus* fractions. (B) The% viability of MCF-7 cell treated with *H. deflersii* fractions. (C) The% viability of MCF-7 cell treated with *H. micranthus* fractions.

Available literature revealed that ursolic acid exhibited excellent anticancer properties against HepG2 and MCF-7 cells, by down regulating the expression of COX-2 ([@b0100]) and by inducing cell cycle G1/G2 arrest and apoptosis ([@b0050]), respectively. β-sitosterol was found to exhibit anticancer properties against breast, prostate, colon, lung, stomach and ovarian cancer by interfering with multiple cell signaling pathways, including cell cycle and apoptosis ([@b0045]). The possible mechanism of anticancer property of β-sitosterol against human colon cancer cells (HT116) was induction of caspase-3/9 activation, decreasing the anti-apoptotic Bcl-2 protein and mRNA expression, and increasing the release of cytochrome *c* ([@b0060]). Lupeol is widely distributed in several plants and fruits possess many pharmacological properties such as anti-diabetic, antioxidant, cardio protective and anticancer ([@b0135]). It was found to induce apoptosis of MCF-7 cells by down regulating the Bcl-2 and Bcl-xL proteins expressions ([@b0105]). Lupeol exhibited strong anticancer property against human osteosarcoma cells (MNNG/HOS and MG-63) by inducing apoptosis and cell cycle arrest in G0/G1 phase along with down regulation of the PI3-kinase, phospho-protein kinase B, cyclin D1 expression and upregulation of the p21 and p27 expressions ([@b0095]). Taken together the presence of all the three biomarkers in the petroleum ether extracts of *H. deflersii* strongly endorses its strong anticancer property.

3.2. Concurrent analysis of biomarkers ursolic acid, β-sitosterol and lupeol in different *Hibiscus species* by High Performance Thin Layer Chromatography (HPTLC) {#s0070}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 3.2.1. HPTLC method development and validation {#s0075}

The mobile phase selection for the HPTLC analysis was carried out by testing various solvents combinations. Out of these, the combination of chloroform and methanol (97:3, v/v) was found as best mobile phase for the estimation of ursolic acid, β-sitosterol and lupeol. Sharp and compact peaks of ursolic acid, β-sitosterol and lupeol were obtained at R~f~ = 0.22, 0.39 and 0.51, respectively ([Fig. 4](#f0020){ref-type="fig"}A) with clear separation of the biomarkers from matrix and other phytoconstituents ([Fig. 4](#f0020){ref-type="fig"}B) using optimized mobile phase volume (20 mL) and saturation time (20 min). The developed method was found to be quite selective with high baseline resolution. The regression equation/correlation co-efficient (r^2^) for ursolic acid, β-sitosterol and lupeol were found as Y = 1.076X + 58.384/0.9947, Y = 3.741X + 695.05/0.9967 and Y = 5.352X + 209.346/0.9957, respectively in the linearity range 100--1200 ng/spot while the LOD/LOQ (ng) were found as 42.30/128.20, 13.20/40.01 and 31.57/95.68, respectively ([Table 2](#t0010){ref-type="table"}). The recovery/RSD (%) for ursolic acid, β-sitosterol and lupeol were found as 99.09--100.13/1.089--1.24, 98.40--99.63/1.105--1.538 and 99.01--99.75/1.351--1.562, respectively ([Table 3](#t0015){ref-type="table"}). The% RSD for intra-day/inter-day precisions (n = 6) of ursolic acid, β-sitosterol and lupeol were recorded as 1.039--1.106/1.043--1.102, 1.121--1.277/1.116--1.274, and 1.168--1.316/1.160--1.312, respectively, exhibited good precision of the proposed method ([Table 4](#t0020){ref-type="table"}). The robustness of proposed method was checked by making a small deliberate change in the mobile phase composition, saturation time and mobile phase volume and the obtained data were reported in the [Table 5](#t0025){ref-type="table"}. The low values of SD and% RSD indicated that the proposed method was robust.Fig. 4Quantification of ursolic acid, β-sitosterol and lupeol in different fractions of *H. calyphyllus*, *H. deflersii* and *H. micranthus* by HPTLC at λ = 575 nm \[mobile phase: chloroform: methanol (97:3)\]. (A) Chromatogram of standard ursolic acid (R~f~ = 0.22), β-Sitosterol (R~f~ = 0.39) and lupeol (R~f~ = 0.51) (B) 3-D display of all tracks (C) Chromatogram of *H. deflersii* petroleum ether fraction \[HdP (ursolic acid, spot 5, R~f~ = 0.22; β-Sitosterol, spot 7, R~f~ = 0.39; lupeol, spot 8, R~f~ = 0.51)\]. (D) Chromatogram of *H. micranthus* petroleum ether fraction \[HmP (ursolic acid, spot 6, R~f~ = 0.22; β-Sitosterol, spot 8, R~f~ = 0.39; lupeol, spot 9, R~f~ = 0.51)\].Table 2R~f~, Linear regression data for the calibration curve of ursolic acid, β-sitosterol and lupeol (n = 6).ParametersUrsolic acidβ-sitosterolLupeolLinearity range (ng/spot)100--1200100--1200100--1200Regression equationY = 1.076X + 58.384Y = 3.741X + 695.05Y = 5.352X + 209.346Correlation (r^2^) coefficient0.9947 ± 0.0050.9967 ± 0.00010.9957 ± 0.002Slope ± SD1.076 ± 0.0133.741 ± 0.0145.352 ± 0.051Intercept ± SD58.384 ± 8.131695.05 ± 11.32209.346 ± 8.727Standard error of slope0.0050.0060.021Standard error of intercept3.3184.623.562Rf0.22 ± 0.0020.39 ± 0.0010.51 ± 0.002LOD (ng)42.3013.2031.57LOQ (ng)128.2040.0195.68Table 3Recovery as accuracy studies of the proposed HPTLC Method (n = 6).Percent (%) of ursolic acid, β-sitosterol and lupeol added to analyteTheoretical concentration of ursolic acid, β-sitosterol and lupeol (ng/μL)Ursolic acidβ-sitosterolLupeolConcentration found (ng/μL) ± SD% RSD% RecoveryConcentration found (ng/μL) ± SD% RSD% RecoveryConcentration found (ng/μL) ± SD% RSD*% Recovery*0200198.18 ± 2.161.08999.09197.14 ± 2.181.10598.57199.03 ± 2.691.35199.5150300298.02 ± 3.571.19799.34297.8 ± 4.191.40799.26299.27 ± 4.181.39699.75100400400.52 ± 4.891.220100.13398.53 ± 5.811.45799.63396.07 ± 6.091.53799.01150500498.79 ± 6.191.24099.75492.03 ± 7.571.53898.40498.58 ± 7.791.56299.71Table 4Precision of the proposed HPTLC Method (n = 6).Conc. of standard added (ng/spot)Ursolic acidβ-sitosterolLupeolIntra-day PrecisionInter-day PrecisionIntra-day PrecisionInter-day PrecisionIntra-day PrecisionInter-day PrecisionAverage Conc. found ± SD%RSDAverage Conc. found ± SD%RSDAverage Conc. found ± SD%RSDAverage Conc. found ± SD%RSDAverage Conc. found ± SD%RSDAverage Conc. found ± SD%RSD200197.25 ± 2.051.039192.61 ± 2.011.043198.88 ± 2.231.121196.20 ± 2.191.116196.02 ± 2.291.168190.42 ± 2.211.160400399.59 ± 4.191.048396.80 ± 4.131.040397.21 ± 4.791.205394.54 ± 4.731.198398.95 ± 5.211.305397.08 ± 5.171.301600595.33 ± 6.591.106591.61 ± 6.521.102595.74 ± 7.611.277593.07 ± 7.561.274597.08 ± 7.861.316595.21 ± 7.811.312Table 5Robustness of the proposed HPTLC Method (n = 6).Optimization conditionUrsolic acidβ-sitosterolLupeolSD%RSDSD%RSDSD%RSD*Mobile phase composition; (Chloroform: methanol; 97:3)*(96.5: 3.5)2.890.9943.871.2965.111.717(97: 3)2.991.0223.921.3155.191.739(97.5: 2.5)3.021.0293.991.3365.271.771  *Mobile phase volume (for saturation)*(18 mL)2.890.9973.761.2655.261.746(20 mL)2.870.9783.791.2745.291.756(22 mL)2.910.9883.811.2805.311.763  *Duration of saturation*(10 min)2.820.9553.821.2815.071.683(20 min)2.860.9653.841.2905.031.670(30 min)2.780.9453.881.3045.091.690

### 3.2.2. HPTLC analysis of anticancer biomarkers ursolic acid, β-sitosterol and lupeol in different fractions of *Hibiscus* species {#s0080}

The developed HPTLC method was employed in the estimation of ursolic acid, β-sitosterol and lupeol in the different fractions of *Hibiscus* species ([Table 6](#t0030){ref-type="table"}). The quantities (μg/mg of the dried weight of extracts) of biomarkers ursolic acid/β-sitosterol/lupeol in different fractions were found in the following order: HdP (5.50/11.85/7.47) \> HmP (4.03/8.57/5.37) \> HcP (1.51/5.43/0.42) \> HmT (3.20/0.23/0.81) \> HdC (1.27/0.59/0.74) \> HdE (1.19/0.049/0.11) \> HcC (0.06/0.098/0.06). This finding clearly indicated that out of fifteen fractions of all the three *Hibiscus* species, -- *H. deflersii* petroleum ether fraction (HdP) and *H. micranthus* petroleum ether fraction (HmP) contains the highest quantity of all the biomarkers ([Fig. 4](#f0020){ref-type="fig"}C and D) followed by other fractions. These biomarkers were found completely absent in *H. deflersii* toluene fraction (HdT), *H. calyphyllus* toluene fraction (HcT), *H. micranthus* ethyl acetate fraction (HmE) and the n-butanol fractions of all three species. Several analytical methods like HPLC, HPTLC has been reported for the quantitative analysis of ursolic acid, β-sitosterol and lupeol in different plant extracts like, estimation of β-sitosterol by HPTLC in the aerial parts of *Tinospora cordifolia* and *Calotropis gigantia* ([@b0010]), lupeol estimation by HPTLC in the leaves of different species of genus *Ficus* ([@b0030], [@b0025], [@b0020]), estimation of ursolic acid in *Rabdosia rubescens* by RP-HPLC ([@b0150]) and in human plasma by UPLC-MS ([@b0145]), but we did not find any literature on the concurrent estimation of these biomarkers in *Hibiscus* species. Hence we are privileged to report this maiden research on the estimation of cytotoxic biomarkers ursolic acid, β-sitosterol and lupeol in *H. calyphyllus*, *H. deflersii* and *H. micranthus* fractions along with their comparative cytotoxic potential against MCF-7 and HepG2 cells.Table 6HPTLC analysis of ursolic acid, β-Sitosterol and lupeol in different fractions of *H. calyphyllus*, *H. deflersii* and *H. micranthus.*[S. No](http://S.%20No){#ir005}.SamplesUrsolic acid content (µg/mg of dried weight of extract)β-sitosterol content (µg/mg of dried weight of extract)Lupeol content (µg/mg of dried weight of extract)1*H. deflersii* petroleum ether fraction (HdP)5.50 ± 0.1711.85 ± 0.267.47 ± 0.232*H. micranthus* petroleum ether fraction (HmP)4.03 ± 0.118.57 ± 0.255.37 ± 0.163*H. calyphyllus* petroleum ether fraction (HcP)1.51 ± 0.035.43 ± 0.190.42 ± 0.0044*H. micranthus* toluene fraction (HmT)3.20 ± 0.080.23 ± 0.0030.81 ± 0.0075*H. deflersii* toluene fraction (HdT)Not detectedNot detectedNot detected6*H. calyphyllus* toluene fraction (HcT)Not detectedNot detectedNot detected7*H. micranthus* chloroform fraction (HmC)Not detected0.062 ± 0.00090.41 ± 0.0068*H. deflersii* chloroform fraction (HdC)1.27 ± 0.030.59 ± 0.010.74 ± 0.019*H. calyphyllus* chloroform fraction (HcC)0.06 ± 0.0010.098 ± 0.0010.06 ± 0.00110*H. micranthus* ethyl acetate fraction (HmE)Not detectedNot detectedNot detected11*H. deflersii* ethyl acetate fraction (HdE)1.19 ± 0.020.049 ± 0.00050.11 ± 0.00112*H. calyphyllus* ethyl acetate fraction (HcE)0.015 ± 0.0001Not detectedNot detected13*H. micranthus* n-butanol fraction (HmB)Not detectedNot detectedNot detected14*H. deflersii* n-butanol fraction (HdB)Not detectedNot detectedNot detected15*H. calyphyllus* n-butanol fraction (HcB)Not detectedNot detectedNot detected

4. Conclusion {#s0085}
=============

With the knowledge about the mechanism of anticancer activity of all the three biomarkers we postulates that the *H. deflersii* exhibited its anticancer effect by inducing cell cycle (G1/G2) arrest and apoptosis, inducing the activation of caspase-3/9, increasing the release of cytochrome *c* and down regulating the Bcl-2 and Bcl-xL proteins expressions. We suggest that *H. deflersii* (Petroleum ether fraction) can be further subjected to the isolation of active cytotoxic phytoconstituents and establishment of their mechanism of action. The maiden HPTLC method developed for the concurrent analysis of ursolic acid, β-sitosterol and lupeol may be further employed for the in-process quality control of herbal formulation containing the said biomarkers.
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